Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer
Cantargia AB today announced that the clinical trial application for the phase Ib/II clinical study TRIFOUR has received approval by the regulatory authority and ethics committee in Spain. This study broadens Cantargia’s clinical program to include triple negative breast cancer (TNBC) and will investigate nadunolimab (CAN04) in combination with chemotherapy in up to approximately 120 patients with TNBC. The first patient is expected to be enrolled in November 2021.The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is Cantargia’s most advanced candidate and is